Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Receivables - Other: 2011-2022

Historic Receivables - Other for Lineage Cell Therapeutics (LCTX) over the last 11 years, with Dec 2022 value amounting to $581,000.

  • Lineage Cell Therapeutics' Receivables - Other was N/A to $549,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $549,000, marking a year-over-year change of. This contributed to the annual value of $581,000 for FY2022, which is 8.60% up from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Receivables - Other stood at $581,000 for FY2022, which was up 8.60% from $535,000 recorded in FY2021.
  • Lineage Cell Therapeutics' Receivables - Other's 5-year high stood at $581,000 during FY2022, with a 5-year trough of $7,000 in FY2019.
  • In the last 2 years, Lineage Cell Therapeutics' Receivables - Other had a median value of $558,000 in 2021 and averaged $558,000.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Receivables - Other crashed by 97.98% in 2019 and then climbed by 8.60% in 2022.
  • Lineage Cell Therapeutics' Receivables - Other (Yearly) stood at $346,000 in 2018, then plummeted by 97.98% to $7,000 in 2019, then reached $535,000 in 2021, then rose by 8.60% to $581,000 in 2022.